<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01493648</url>
  </required_header>
  <id_info>
    <org_study_id>MOP 114917</org_study_id>
    <nct_id>NCT01493648</nct_id>
  </id_info>
  <brief_title>Muscle-Related Side Effects of Statins: Functional Impact, Mechanisms, and Potential Relief With Vitamin D Supplementation</brief_title>
  <official_title>Muscle-Related Side Effects of Statins: Functional Impact, Mechanisms, and Potential Relief With Vitamin D Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposal will explore muscle function (strength and endurance) in men and women&#xD;
      suffering from statin-induced muscle symptoms. The mechanisms responsible for these muscle&#xD;
      symptoms will be explored. Also, the investigators will assess the potential usefulness of&#xD;
      vitamin D supplementation in a randomized control trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Statins are a class of drugs that are widely prescribed to lower blood cholesterol levels.&#xD;
      Although they have few side effects, many patients report muscle pain, cramps, and weakness&#xD;
      when using these drugs. We know very little on the real impact of these muscle symptoms on&#xD;
      patient quality of life, especially in relation to muscle strength and endurance.&#xD;
&#xD;
      Patients under statin therapy will stop medication for 2 months. Results from blood sample,&#xD;
      muscle function and muscle biopsy (in some participants) will be compared with baseline.&#xD;
      Participants will then take vitamin D supplementation or placebo for one month. Thereafter,&#xD;
      statin will be reintroduced for two months while continuing vitamin D or placebo&#xD;
      supplementation. At the end of that time, measures from blood sample, muscle function and&#xD;
      muscle biopsy will be compared with other visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain score</measure>
    <time_frame>Change from baseline at 2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in muscle function testing</measure>
    <time_frame>Change from baseline at 2 months</time_frame>
    <description>Strenght and endurance evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in muscle histology</measure>
    <time_frame>Change from baseline at 2 months</time_frame>
    <description>Histological, ultrastructural and metabolic assessment of muscle biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain score</measure>
    <time_frame>Change from baseline at 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle function testing</measure>
    <time_frame>Change from baseline at 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle histology</measure>
    <time_frame>Change from baseline at 5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>HMG COA Reductase Inhibitor Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Participants will receive weekly doses of 30,000 IU of vitamin D for 3 months.</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>Cholecalciferol, D-tabs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo (lactose 100 mg) for 3 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  statin therapy&#xD;
&#xD;
          -  healthy and sedentary or moderately physical active&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current treatment with other lipid-lowering drugs&#xD;
&#xD;
          -  Natural medicine affecting lipid metabolism&#xD;
&#xD;
          -  CK levels above the normal range&#xD;
&#xD;
          -  Clinical vitamin D deficiency&#xD;
&#xD;
          -  Impaired liver or kidney function&#xD;
&#xD;
          -  Untreated hypo- or hyperthyroidism&#xD;
&#xD;
          -  Treatment with other medications known to increase risk of myopathy&#xD;
&#xD;
          -  Existing infection requiring antibiotic therapy&#xD;
&#xD;
          -  Consumption of greater than 60 ml of grapefruit juice per day&#xD;
&#xD;
          -  Inherited muscle disorders or myopathy&#xD;
&#xD;
          -  Polymyositis or inflammatory myopathy&#xD;
&#xD;
          -  Use of corticosteroids&#xD;
&#xD;
          -  Comorbidities resulting in muscle or bone pain&#xD;
&#xD;
          -  History of elevated CK&#xD;
&#xD;
          -  Unexplained cramps&#xD;
&#xD;
          -  Known sickle cell trait&#xD;
&#xD;
          -  Cancer within the 5 years prior to study entry&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Stroke, coronary artery or peripheral vascular disease&#xD;
&#xD;
          -  Physical disability or previous injury interfering with exercise testing&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Depression (in last 3 years) or treatment with antidepressants&#xD;
&#xD;
          -  Use of anti-psychotic drugs&#xD;
&#xD;
          -  Alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis R Joanisse, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Bergeron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Quebec-Universite Laval</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jérôme Frenette, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Quebec-Universite Laval</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Québec - CHUL</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>November 29, 2011</study_first_submitted>
  <study_first_submitted_qc>December 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2011</study_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>statins</keyword>
  <keyword>side effects</keyword>
  <keyword>muscle</keyword>
  <keyword>vitamin D</keyword>
  <keyword>biopsy</keyword>
  <keyword>strength</keyword>
  <keyword>fatigue</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

